38
- Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of
lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney
disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet.
2011;377(9784):2181–92. - Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Writing Group
on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of
Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol.
2012;60(16):1581–98. - Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients
with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48. - Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC, Tarng DC. Volume overload cor-
relates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int.
2014;85(3):703–9. - Schork A, Woern M, Kalbacher H, Voelter W, Nacken R, Bertog M, et al. Association of plas-
minuria with overhydration in CKD patients. Clin J Am Soc Nephrol. 2016;11(5):761–9. - Passero CJ, Hughey RP, Kleyman TR. New role for plasmin in sodium homeostasis. Curr Opin
Nephrol Hypertens. 2010;19(1):13–9. - Andersen H, Friis UG, Hansen PB, Svenningsen P, Henriksen JE, Jensen BL. Diabetic
nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and
urokinase and activation of amiloride-sensitive current in collecting duct cells. Nephrol Dial
Transplant. 2015;30(5):781–9. - Smyth A, O'Donnell MJ, Yusuf S, Clase CM, Teo KK, Canavan M, Reddan DN, Mann JF. Sodium
intake and renal outcomes: a systematic review. Am J Hypertens. 2014;27(10):1277–84. - Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink
HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibi-
tion compared with dual blockade in lowering proteinuria and blood pressure: randomised
controlled trial. BMJ. 2011;343:d4366. - Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-term prog-
nostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and
home blood pressure measurements. Hypertension. 2013;62(1):168–74. - Shimbo D, Kent ST, Diaz KM, Huang L, Viera AJ, Kilgore M, et al. The use of ambulatory
blood pressure monitoring among Medicare beneficiaries in 2007-2010. J Am Soc Hypertens.
2014;8(12):891–7. - Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA.
2014;311(21):2216–24. - Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, et al. Effect of spironolactone
on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45. - Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone
versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-
resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet.
2015;386(1008):2059–68. - Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin
Hypertens (Greenwich). 2004;6(5):283–7.
F. A r t u nc